OQS
SPRO icon

Occudo Quantitative Strategies’s Spero Therapeutics SPRO Stock Holding History

Occudo Quantitative Strategies’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,421
Closed -$41.2K – 953
2026
Q1 		$41.2K Buy
+16,421
New +$39K ﹤0.01% 724

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Occudo Quantitative Strategies's SPRO Position: Q2 2026 in Review

Occudo Quantitative Strategies sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 16,421 shares — an estimated $41.2K sold.

Occudo Quantitative Strategies first reported a position in SPRO in Q1 2026 and held it in 1 quarter. The position peaked at $41.2K in Q1 2026. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Occudo Quantitative Strategies reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 16,421 Spero Therapeutics shares in Q2 2026, an estimated $41.2K.
  • Occudo Quantitative Strategies first reported a position in Spero Therapeutics in Q1 2026 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Spero Therapeutics position peaked at $41.2K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.